Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

MLA

Pipe, S. W., et al. “Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.” New England Journal of Medicine, vol. 388, no. 8, Feb. 2023, pp. 706–18. EBSCOhost, https://doi.org/10.1056/NEJMoa2211644.

APA

Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O’Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J.-, Hermans, C. R. J. R., Klamroth, R., & Lemons, R. (2023). Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine, 388(8), 706–718. https://doi.org/10.1056/NEJMoa2211644

Chicago

Pipe, S. W., F. W. G. Leebeek, M. Recht, N. S. Key, G. Castaman, W. Miesbach, S. Lattimore, et al. 2023. “Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.” New England Journal of Medicine 388 (8): 706–18. doi:10.1056/NEJMoa2211644.